adaptive trial

A September 2020 appraisal of REMAP-CAP’s hydrocortisone results in critically ill patients with COVID-19. Dan Horner and Simon Carley explain adaptive trials, Bayesian analysis and organ support outcomes, weighing the findings against early stopping, treatment crossover and the wider corticosteroid evidence.